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The incidence of anemia of chronic disease (ACD) is underestimated, increases with age, and affects about 30% of the elderly. ACD 
treatment is currently based on the pharmacotherapy of diseases that caused anemia, erythropoiesis-stimulating agents, and parenteral 
administration of iron supplementation in case of iron deficiency. Increasing knowledge on the pathophysiology of ACD has resulted 
in the burst of research on the development of new drugs that are focused on three main areas. The first group of drugs includes 
substances that inhibit hepcidin transcription, namely direct and indirect bone morphogenetic protein 
6 (BMP6) inhibitors and/or SMAD signaling pathway inhibitors, and drugs that regulate hepcidin transcription through STAT3 signaling 
pathway. The second group of drugs includes direct hepcidin inhibitors (e.g., aptamers, anticalin proteins, monoclonal antibodies) or 
substances that inhibit the binding of hepcidin to ferroportin. The third group of drugs improves erythropoiesis mainly by upregulation 
of erythropoietin and/or inhibition of proinflammatory cytokines. In the latter group, hypoxia-inducing factor stabilizers and IL-6 or 
TNFα antagonists are particularly important. This article discusses new drug groups and substances that are in different phases of 
development, including both preclinical and clinical studies, and focuses on the prospects of their use in ACD.
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Introduction
The global prevalence of anemia of chronic disease (ACD), also known 
as anemia of inflammation, is not fully estimated [1]. The incidence of 
ACD increases with age, and in the elderly population it accounts for 
approximately one-third of all anemia cases [2, 3]. ACD can develop 
in the course of infections, malignancies, and autoimmune diseases. 
The etiology of this type of anemia is complex and it is associated with 
a decrease in red blood cells (RBCs) production and decreased survival. 
The activity of proinflammatory cytokines, including tumor necrosis 
factor α (TNFα) and interferons, results in decreased availability of 
iron for erythropoiesis, reduced response to erythropoietin (EPO), 
and decreased EPO synthesis, which in turn inhibit proliferation and 
differentiation of erythroid progenitor cells and increase erythrocyte 
turnover and their degradation by macrophages. Hepcidin plays 
a central role in reducing the bioavailability of iron, and its expression 
is regulated by proinflammatory cytokines, in particular, interleukin 6 
(IL-6) [4, 5]. However, other molecules, such as IL-10, interferon γ (IFN-γ), 
IL-1β, and lipopolysaccharide, also serve as hepcidin inducers [6]. Many 
proteins have been described to be involved in the regulation of hepcidin 
synthesis, and thus they may become a target for ACD therapy. These 
include bone morphogenetic protein (BMP), hemojuvelin (HJV), activin 
receptor-like kinases 2 and 3 (ALK-2 and ALK-3), and erythroferrone 
(ERFE) [5, 7]. Also EPO can directly reduce hepcidin production by 
inhibiting the BMP-small mothers against decapentaplegic proteins 
(BMP-SMAD) pathway [8] and also via hypoxia-inducible factor (HIF) 
signaling [9].
Currently, ACD therapy is limited to the treatment of the underlying 
disease that is responsible for inflammatory response. Additionally, 
erythropoiesis-stimulating agents (ESAs), in particular human 
recombinant erythropoietin (EPO), are also administered. Sometimes 
iron supplementation is necessary. Better understanding of the 
regulation of iron metabolism in the presence of inflammation, with 
particular focus on the role of hepcidin, proinflammatory cytokines, and 
HIF in erythropoiesis, has caused a burst of research on the development 
of new drugs for the treatment of ACD. These studies, focusing on 
three major research areas, are in various stage of development from 
experimental stage through preclinical research to clinical studies. The 
first group of studies evaluates the influence of various substances 
on hepcidin production. The second group examines the substances 
that inhibit the effects of hepcidin release. This group contains direct 
hepcidin inhibitors (hepcidin neutralizers and anti-hepcidin monoclonal 
antibodies) or substances that are able to inhibit binding of hepcidin to 
ferroportin. Finally, the third group of studies focuses on erythropoiesis 
inducers that upregulate EPO, stabilize HIF, and block proinflammatory 
cytokines.
Hepcidin production inhibitors
Hepcidin production inhibitors downregulate hepcidin gene (hepcidin 
antimicrobial peptide gene [HAMP]) in hepatocytes (Fig. 1). Hepcidin 
transcription can be inhibited as a result of the inhibition of SMAD and/
or signal transducer and activator of transcription (STAT) signaling 
pathways. It can be achieved in a variety of mechanisms, the most 
important of which seems to be BMP or BMP receptor interaction and 
blocking of IL-6 or IL-6 receptor. Downstream signaling from BMP 
receptor is mediated through SMAD1/5/8 pathway while signaling 
from IL-6 receptor is mediated through Janus-activated kinases (JAK)/
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STAT3 signaling pathway. The BMP-SMAD pathway is activated 
by BMP-2 and BMP-6 through BMP receptors forming complexes 
with ALK-2 and ALK-3, and HJV as a BMP receptor on liver cells 
enhances the transmission of this signal [7, 10].
Drugs/substances affecting BMP6 pathway
Currently, a number of substances affecting BMP6 pathways 
are studied. In two models, murine and rat, the use of anti-BMP6 
antibodies led to an increase in hemoglobin (Hb),  a decrease in iron 
deposition in tissues, and a reduction in ESA doses needed to treat 
ACD [11]. Recently, LY3113593, a human anti-BMP6 monoclonal 
antibody, is gaining more interest. LY3113593 blocks binding of BMP6 
to its receptor, which leads to an increase in iron concentration, an 
increase in transferrin saturation, and a decrease in hepcidin level. In 
a study performed in a group of patients with chronic kidney disease 
(CKD), LY3113593 increased Hb and caused a decrease in ferritin 
level in comparison with placebo [12].
Other drugs affecting BMP-6 receptor currently tested in clinical trials 
include: LDN-193189, modified heparin (e.g., roneparstat), TP-0184, 
and a group of drugs related to HJV.  LDN-193189 is a selective 
inhibitor of the BMP kinase type 1 receptor [13]. TP-0184 is an ALK-2 
inhibitor that reduces hepcidin mRNA and improves Hb concentration 
in preclinical studies in mice [14]. Modified heparin with reduced 
anticoagulation ability binds BMP-6 and blocks hepcidin expression, 
as demonstrated in in vitro and in vivo animal models [15, 16].
The ability to inhibit hepatic BMP-SMAD signaling, reduce hepcidin 
levels, increase ferroportin expression, and increase serum iron 
levels has also been demonstrated for protein-soluble HJVFc (HJV.
Fc). HJV.Fc consists of extracellular domain of HJV conjugated with 
human IgG Fc fragment [10, 17]. Currently, other potential drugs, e.g., 
h5F9.23 and  h5F9-AM8, which interact with HJV, are experimentally 
investigated [18]. Administration of a single dose of ABT-207 or 
H5F9-AM8 in rats and monkeys resulted in prolonged suppression of 
hepcidin production and an increase in serum iron concentration [19]. 
H5F9-AM8 was tested in animal models of ACD and iron-refractory 
iron-deficiency anemia (IRIDA), resulting in reduction of hepcidin and 
improvement of anemia in all cases [20].
Druggable targets associated with proinflammatory 
cytokines
Clinically available drugs include a humanized anti-IL-6 receptor 
antibody, tocilizumab, and  a chimeric (human–murine) antibody 
against IL-6, siltuximab. Tocilizumab is used in rheumatoid arthritis. 
As an improvement of RBC parameters have been observed during 
the treatment, tocilizumab has become a new potential drug for 
ACD [21, 22]. Tocilizumab was successfully used in the treatment 
of anemia in patients with Castleman’s disease [22] and in patients 
with malignant tumors [23]. Reduced serum hepcidin level and 
improvement of anemia in patients with Castleman’s disease [24, 25], 
myeloma, and other lymphoproliferative cancers [26] have been 
reported for siltuximab. An improvement in RBC parameters has also 
been demonstrated in the treatment of solid tumors [27]. Another IL-6 
receptor antibody, MR16-1, was tested in murine models. MR16-1 has 
been shown to improve Hb parameters in cancer-associated anemia 
[23]. Other substances affecting hepcidin production by modulation of 
signaling pathways in hepatocytes have been tested experimentally. 
In murine models, natural and synthetic STAT3 inhibitors have been 
shown to inhibit hepcidin expression in macrophages [28]. MaR1 
Fig. 1. Hepcidin transcription inhibitors 
ACVR2A – activin receptor type 2A; ALK3/2 – activin receptor-like kinase 3/2; BMP-6 – bone morphogenetic protein 6; BMPR2 – bone 
morphogenetic protein receptor 2; ERFE – erythroferron; EGFR – epidermal growth factor receptor; HAMP – hepcidin antimicrobial peptide; 
HJV – hemojuvelin; HFE – human hemochromatosis protein; IL-6 – interleukin6; IL-6R – IL-6 receptor; JAK – Janus-activated kinases; SMAD 
– small mothers against decapentaplegic proteins; STAT3 – signal transducer and activator of transcription 3; TFR2 – transferrin receptor 2; 
TMPRSS6 – transmembrane protease serine 6
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inhibits inflammatory response, including hepcidin expression, by 
affecting the IL-6/STAT3 signaling pathway and then reducing the 
severity of anemia symptoms [29].
Potential role of ERFE
ERFE is a physiological regulator of hepcidin, which is synthesized 
and secreted by erythroblasts in the bone marrow and other tissues in 
response to EPO. ERFE inhibits hepcidin transcription by an unknown 
mechanism that involves BMP6 pathway and probably some known 
membrane receptors [30, 31]. ERFE antagonists and agonists, and 
also other substances involved in the BMP6 signaling pathway, 
may prove useful in the prevention and treatment of iron disorders. 
However, a recently published study suggested a correlation 
between increased ERFE levels and death/cardiovascular events in 
hemodialysis patients with CKD, which is further enhanced by the 
administration of ESA [30]. Therefore, the potential use of ERFE in 
anemia requires further research and careful determination of patient 
groups who may benefit from such a therapy.
Other possibilities of hepcidin production inhibition
It has been shown that hepcidin production can be inhibited 
by thiazolidinediones, testosterone, estrogens, vitamin D, 
and substances of plant origin (e.g., Angelica sinensis). New 
thiazolidinediones are studied in the treatment of anemia. These 
drugs may affect hepcidin expression through various pathways, 
including SMAD1/5/8 signaling pathway, extracellular signal-
regulated kinases 1/2 (ERK1/2) and TMPRSS6, and also probably 
by indirectly affecting ERFE-mediated hepcidin production [32].
In vitro and in vivo studies have shown that vitamin D inhibits the 
expression of proinflammatory cytokines and directly inhibits 
hepcidin transcription by interaction of vitamin D receptor with the 
HAMP promoter [33, 34]. In a population of children with chronic 
inflammatory bowel disease, high levels of cholecalciferol (≥30 ng/mL) 
were associated with higher Hb levels, while low levels correlated 
with elevated hepcidin and lower Hb concentration [35]. However, not 
all studies confirmed the effect of vitamin  D supplementation on the 
levels of proinflammatory cytokines, ferritin, or hepcidin [36]. A meta-
analysis and systematic review of literature did not confirm the effect 
of cholecalciferol on IL-6 or C-reactive protein (CRP) levels [37]. 
On the other hand, Smith and colleagues showed that high doses 
of vitamin D significantly reduced hepcidin levels in healthy adults 
1 week after the administration of a single dose, without affecting the 
levels of proinflammatory cytokines or ferritin. The authors concluded 
that this may suggest that the effect of vitamin D on hepcidin is 
independent from proinflammatory cytokines or ferritin [38]. In many 
clinical trials, the inverse correlation between vitamin D levels and 
anemia has been reported. It is now believed that vitamin D is an 
important factor involved in the pathogenesis of anemia [39, 40].
Testosterone inhibits hepcidin by upregulation of the epidermal 
growth factor receptor (EGFR) signaling in the liver [41] and 
downregulates hepcidin transcription by its influence on BMP-SMAD 
signaling pathway [42]. The administration of testosterone increases 
the concentration of Hb in men with reduced testosterone levels, in 
case of anemia of both known and unknown cause as demonstrated 
in a study of nearly 800 men, including 126 with anemia [43]. 
Similarly, 17-β-estradiol could be considered a drug for anemia in the 
elderly women because it has also been shown to inhibit hepcidin 
transcription. Inhibition of hepcidin transcription results from the 
activity of estrogens on HAMP-associated gene promoters [44].
Angelica sinensis polysaccharide (ASP), a polysaccharide 
obtained from the root of the Angelica sinensis plant, inhibits 
hepcidin expression and may potentially improve RBC parameters 
in patients with anemia. The efficacy of ASP in the treatment of 
anemia associated with CKD has been demonstrated in rats. ASP 
inhibited hepcidin production, increased the amount of iron available 
for erythropoiesis by its mobilization from the liver and spleen, and 
increased EPO levels [45]. Previous data have shown that regular 
supplementation of Angelica sinensis in hemodialyzed patients 
improved anemia in patients resistant to recombinant human EPO 
therapy [46]. It is believed that ASP inhibits hepcidin expression 
by inhibiting the expression and/or phosphorylation of JAK1/2, 
SMAD1/5/8, and ERK1/2 while upregulating SMAD7 [47].
Direct hepcidin inhibitors and agents 
preventing hepcidin from binding to 
ferroportin
Another group of drugs that affect hepcidin are direct hepcidin 
inhibitors and drugs that prevent hepcidin from binding to ferroportin 
(Fig. 2). Direct neutralization of hepcidin is possible with monoclonal 
antibodies (AB 12B9M) as well as anticalin proteins (e.g., PRS-080), 
aptamers (e.g., NOX-H94), or guanosine 5'-diphosphate (GDP). 
Anticalins are a class of ligand-binding proteins designed based on a 
lipocalin scaffold. Aptamers are oligonucleotides (short DNA or RNA 
fragments) or peptides that bind specifically to a specific molecule. 
PRS-080 is a hepcidin-binding anticalin protein [48]. In cynomolgus 
monkeys, PRS-080 has been shown to reduce hepcidin and increase 
iron levels [49]. However, there are currently ongoing studies 
assessing the effects of PRS-080 anticalin proteins in patients with 
anemia in the course of CKD (NCT03325621) [50]. On the other 
hand, the aptamer NOX-H94 (lexaptepid pegol [LP]) is a pegylated 
oligoribonucleotide that binds to hepcidin with high affinity and blocks 
its biological function. The effects of this aptamer were confirmed in 
vitro and in vivo [51]. The pharmacokinetics, pharmacodynamics, 
and safety study of NOX-H94 carried out in 64 healthy volunteers has 
shown decrease in hepcidin level and increase in iron and transferrin 
saturation in comparison with placebo [52]. LP has been used to 
treat ACD in patients with multiple myeloma and lymphoma. LP 
caused a significant increase in Hb (≥1 g/dL) in 5 out of 12 patients. 
Responders experienced increase in Hb concentration in RBCs and 
reticulocytes, and a decrease in soluble transferrin receptor (sTFR) 
level. These results confirm the hypothesis on the efficacy of hepcidin 
inhibition in the treatment of cancer-related anemia, especially in 
functional iron deficiency. However, the patients with symptomatic 
iron deficiency, hypochromic anemia, without excessive levels of 
ferritin, and high sTFR levels were more likely to respond to LP [53].
The group of monoclonal antibodies that serve as direct inhibitors 
of hepcidin includes Ab12B9m and LY2787106. Ab12B9m is fully 
human monoclonal IgG2 antibody that binds both human and 
monkey hepcidin, which is currently under clinical development 
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[54]. LY2787106 is also a fully humanized monoclonal antibody. In 
phase 1 clinical trials, the use of LY2787106 in tumor-associated 
anemia resulted in a dose-dependent increase in iron concentration 
and transferrin saturation, with good tolerance profile [55]. GDP also 
seems to be a promising agent. It is a direct hepcidin inhibitor with 
efficacy confirmed in in vitro studies. In animal experiments in mice 
with ACD, administration of GDP in combination with iron sulfate 
resulted in an increase in Hb concentration, iron, and ferroportin 
(FPN) expression and decrease in ferritin level [56].
Potential drugs that prevent hepcidin from binding to ferroportin 
include: LY2928057, fursultiamine, thioxolone, and chloroquine. 
These compounds prevent internalization and lysosomal degradation 
of ferroportin. As a result, hepcidin cannot inhibit iron transport in 
intestinal epithelial cells or macrophages [57, 58]. LY2928057 is 
a fully humanized IgG4 monoclonal antibody that binds with human 
ferroportin. In patients with anemia in the course of CKD, LY2928057 
improved iron parameters but did not increase Hb level. Therefore, 
the need for concomitant ESAs treatment was suggested [59].
Agents affecting EPO and proinflammatory 
cytokines
Another option for treating ACDs is to enhance erythropoiesis by 
affecting EPO pathway or interfere with inflammatory processes 
(Fig. 3). This mechanism is utilized by HIF prolyl hydroxylase 
inhibitors (HIF-PHI), i.e., molecules that stabilize HIF subunits. The 
use of  HIF-PHI, similar to hypoxia, activates genes that regulate EPO 
concentration and contribute to the regulation of iron metabolism. 
As a result, there is an increase in EPO level and iron availability 
for erythropoiesis [9, 60]. EPO stimulates erythropoiesis, and via 
activation of EPO receptor it induces ERFE and blocks hepcidin 
activity [61].
HIF hydroxylase inhibitors appear to be beneficial, especially 
for patients with CKD-associated anemia. By increasing EPO 
concentration, the need for ESAs that are associated with increased 
risk of cardiovascular events is reduced. In addition, HIF-PHI can be 
administered orally which is the preferred route for patient treatment 
[60]. The following  HIF-PHI are currently tested: molidustat [62], 
GSK1278863 [63], or FG-4592 [64]. The research is focused mainly 
on patients with CKD. Phase 3 trials of the safety, tolerability, 
and efficacy of molidustat in patients with CKD (both on and off 
dialysis) are currently ongoing [62, 65]. Phase 3 on the efficacy of 
GSK1278863 in patients with CKD showed a significant increase 
in the reticulocyte count and other RBC parameters, indicating that 
further testing is warranted [63]. Also, phase 2 trials of roxadustat 
(FG-4592) has shown its potential for oral therapy in dialyzed anemic 
patients with CKD [66].
The trials with HIF hydroxylase inhibitors focus not only in the 
treatment of ACDs but also in other studies. HIF stabilization with 
HIF-PHI is important in regulating hematopoietic stem cell (HSC) 
proliferation and HSC regeneration processes. These properties 
can be used to protect the bone marrow during radiation therapy, or 
to increase mobilization in transplant procedures using granulocyte 
colony-stimulating factor (GCS-F) and plerixafor. Therefore, HIF 
Fig. 2. Direct and indirect hepcidin inhibitors
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hydroxylase inhibitors may have a potential to improve the effects 
of treatment in transplant recipients or oncology patients [67]. HIF 
also participates in the regulation of multiple processes including: 
apoptosis, angiogenesis, cell proliferation, pH regulation, cellular 
energy metabolism, and glucose transport [9]. Therefore, further 
research on the long-term safety of HIF hydroxylase inhibitors is 
needed, with particular attention to the assessment of the risk of 
tumorigenesis. It should be emphasized that in rat studies, roxadustat 
did not show carcinogenic properties [68]. Another potential threat is 
that HIF stabilization may be associated with an increase in circulating 
fibroblast growth factor 23 (FGF23) level, and high concentrations 
of FGF23 have been associated with cardiovascular complications 
and bone mineralization disorders. However, the increase in FGF23 
caused by HIF-PHI is lower than its increase after administration of 
ESAs [69, 70].
The increase in EPO synthesis can also be caused by monoclonal 
antibodies as discussed earlier, i.e., anti-IL-6 siltuximab [24] and 
anti-IL-6 receptor tocilizumab [21, 24]. TNFα is  a potential target 
for anemia of inflammatory diseases, especially in the course of 
arthritis or inflammatory bowel disease (IBD) [22]. Anti-TNFα drugs 
include etanercept (ETN), adalimumab (ADA), infliximab (IFX), and 
golimumab (GO). ETN is a recombinant receptor protein conjugated 
to the Fc fragment of a human immunoglobulin G1. ETN prevents 
TNFα from binding to the receptor and blocks its effects. Other 
human monoclonal antibodies, ADA and GO, as well as chimeric 
monoclonal antibody IFX and humanized pegylated Fab fragment of 
monoclonal antibody, certolizumab, exert similar effects. In patients 
with IBD, reduced hepcidin level and improved anemia after anti-
TNFα treatment that modulated hepcidin concentration via IL-6 
pathway were observed [71]. It has also been reported that the use of 
anti-TNFα drugs in IBD patients resolves anemia without the need for 
iron supplementation [72]. ETN, ADA, and IFX improved Hb level in 
patients with rheumatoid and psoriatic arthritis [73]. Increased risk of 
carcinogenesis after anti-TNFα therapy has not been confirmed so far; 
however, careful surveillance is needed in the treated patients [74].  It 
should be highlighted that the use of biologicals in the course of IBD 
is associated with the potential risk of hematological complications 
such as neutropenia or the development of lymphomas, especially 
when biologicals are used in combination with other drugs. Further 
studies are needed to estimate the exact risk of these complications 
[75, 76].
Summary
A number of studies on new drugs for the treatment of ACD are 
underway, focusing on various factors involved in iron metabolism 
and erythropoiesis regulation. Drugs and tested substances are 
intended to directly inhibit hepcidin or its transcription, or counteract 
hepcidin activity. The effect of various substances on erythropoiesis 
is also assessed, mainly by stabilizing the HIF and inhibiting 
proinflammatory cytokines. Some of these drugs are already used 
in the treatment of inflammatory bowel disease or in rheumatology, 
while others are in the experimental phase and will take many years 
before their introduction to the routine practice. Intensive research 
Fig. 3. Drugs affecting erythropoietin and pro-inflammatory cytokines 
EPO – erythropoietin; IL-6 – interleukin 6; IL-6R – IL-6 receptor; TNFα – tumor necrosis factor α; HIF – hypoxia-inducible factor
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and a vast array of tested compounds give hope for the development 
of more effective ACD treatments in the coming future.
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